PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.

ABSTRACT:

Background

PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression.

Materials and methods

Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients' characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8^th edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression.

Results

Measure

SUBMITTER: Wu CE 

PROVIDER: S-EPMC7655253 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature